Comparative Pharmacology
Head-to-head clinical analysis: TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT versus TECHNETIUM TC 99M MPI MDP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT versus TECHNETIUM TC 99M MPI MDP.
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT vs TECHNETIUM TC 99M MPI MDP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc 99m albumin aggregated is a radiopharmaceutical that localizes in the pulmonary capillary bed by capillary blockade, allowing for lung perfusion imaging. The aggregated albumin particles are trapped in the pulmonary capillaries, and the Tc 99m emits gamma radiation detectable by gamma cameras.
Technetium Tc-99m medronate (MDP) is a radiopharmaceutical that localizes in bone via chemisorption onto hydroxyapatite crystals, particularly in areas of increased osteoblastic activity. The Tc-99m label emits gamma rays detectable by gamma cameras, allowing imaging of skeletal abnormalities.
1-4 mCi (37-148 MBq) intravenous injection for lung perfusion imaging. Single dose per imaging session.
15-30 mCi (555-1110 MBq) intravenously, single dose, followed by imaging 2-3 hours post-injection.
None Documented
None Documented
Physical half-life of Tc-99m is 6.02 hours; biological half-life of aggregated albumin in lungs is 2-4 hours due to enzymatic degradation and clearance.
Terminal elimination half-life: 6 hours (range 4-8). Clinical context: allows imaging up to 4 hours post-injection; accumulation in bone lesions peaks at 2-4 hours.
Renal: 30-40% within 24 hours (free pertechnetate); fecal: <1% (minor); remainder accumulated in reticuloendothelial system with slow release.
Renal: ~70% eliminated unchanged in urine within 24 hours; biliary/fecal: minimal (<5%)
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical